Fluorescence labeled antibodies against EGFR and VEGF showed high specificity for the target tumor; however, these antibodies could not overcome the disadvantages such as longer time to reaction after injection, and immunogenicity [9, 11]. This evidence concerns the gene EGFR and neoplasm.